Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

livisto int'l, s.l. - amoxicillin trihydrate; potassium clavulanate - tablet - 50/12.5 mg/tablet - amoxicillin and enzyme inhibitor

Malta - Ingliż - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - powder for oral suspension - clavulanic acid 125 mg amoxicillin 875 mg - antibacterials for systemic use

Malta - Ingliż - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - powder for oral suspension - clavulanic acid 125 mg amoxicillin 1000 mg - antibacterials for systemic use

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml;  ; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml   potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml;  ; potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage);  ;   - powder for oral suspension - 250mg, 62.5mg/5ml - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml   potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Malta - Ingliż - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 875 mg clavulanic acid 125 mg - antibacterials for systemic use

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

ceva santé animale - amoxicillin; clavulanic acid - chewable tablet - 62.5 mg/tablet - amoxicillin and enzyme inhibitor - cats, dogs - antibacterial

Stati Uniti - Ingliż - NLM (National Library of Medicine)

rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension usp, 600 mg/5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: • antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: [see clinical pharmacology, microbiology .] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg /ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both s. pneumoniae (penicillin mic ≤ 2 mcg/ml) and the β-lactamase-producing orga

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 1000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 500/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor